Mezagitamab

Table of contents

• What is mezagitamab?
• How does mezagitamab work?
• Which conditions is mezagitamab being studied for?
• How is mezagitamab given?
• What do the clinical trials show?
• What side effects are known?

What is mezagitamab?

Mezagitamab is an investigational antibody. The name ending in "-mab" indicates that it is a monoclonal antibody, a protein designed to bind to a specific target in the body. The clinical trial records do not state a marketing authorisation for mezagitamab, so it is not yet an authorised medicine. The substance data in the registry list no trade names or other names beyond the development name mezagitamab.

How does mezagitamab work?

The trial records provided do not describe the molecular target or mechanism of action of mezagitamab. The conditions studied — chronic primary immune thrombocytopenia and IgA nephropathy — are both immune-related disorders, which suggests an immune-modulating role, but no source in the data states this directly. The mechanism section is therefore left open rather than filled with unverified information.

Which conditions is mezagitamab being studied for?

• Chronic primary immune thrombocytopenia (ITP) — a condition in which the immune system destroys platelets, leading to a low platelet count and an increased risk of bleeding. Two of the three registered trials study mezagitamab in adults with this condition.^[1][2]
• Primary immunoglobulin A nephropathy (IgAN), also known as Berger's disease — a kidney condition in which deposits of immunoglobulin A build up in the kidneys, causing inflammation and protein in the urine. One Phase 3 trial studies mezagitamab in this condition.^[3]

How is mezagitamab given?

In all three registered trials, mezagitamab is given as a subcutaneous injection, meaning an injection under the skin. The registry records list the pharmaceutical form as a subcutaneous injection. The trials include placebo-matching injections for comparison. No oral or intravenous formulation appears in the data.

What do the clinical trials show?

The registry lists three authorised Phase 3 trials of mezagitamab. All are interventional studies and all are in the authorised status, meaning they have received regulatory approval to proceed. The trials are placebo-controlled: participants receive either mezagitamab or a matching placebo injection.

The largest trial enrols 347 participants with IgA nephropathy and measures change from baseline in proteinuria at Week 36, assessed by a urine protein-to-creatinine ratio calculated from a 24-hour urine collection.^[3] Proteinuria means protein in the urine, which is a sign of kidney damage.

Two trials study chronic primary ITP. One enrols 206 participants and measures durable platelet response through Week 24, defined as a platelet count of at least 50,000 per microlitre on at least 4 of the 6 weekly measurements between Week 19 and Week 24.^[1] The other is a follow-up study enrolling 150 participants that evaluates long-term safety and tolerability, measuring the occurrence of treatment-emergent adverse events and serious treatment-emergent adverse events, as well as adverse events leading to permanent withdrawal of mezagitamab.^[2]

No efficacy results are reported in the registry records, because these trials are authorised but not yet completed. The data therefore describe what the trials plan to measure, not what they have found.

What side effects are known?

The registry records provided do not include side effect data from completed trials, and no supplementary sources on side effects were supplied. The follow-up trial in chronic ITP is specifically designed to measure long-term safety and tolerability, including treatment-emergent adverse events and serious treatment-emergent adverse events.^[2] Until results are reported, no side effect profile can be stated from the available data.